ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 ...

Many solid tumors express the CD47 protein on their surface, which serves as a "don't eat me" signal to the body's immune system, allowing the tumor to evade detection. The antibody in this ATC ...

Just a week after dropping the development of its CD47-targeting antibody magrolimab in blood cancers, Gilead Sciences has paused enrolment in clinical trials of the drug in solid tumours ...

Other studies of the CD47-directed antibody in large B cell lymphoma, multiple myeloma and solid tumours are not affected as they don't include azacitidine as a study drug. "While no clear trend ...

Promising pipeline CD47 antigen inhibitors such as IMC-002, MP 0621, HCB-101, PT-217, HX 009, Maplirpacept, IBI 322, ALX-148, HMPL-A83 and others are under different phases of CD47 antigen ...

ALX Oncology (ALXO) will highlight progress across its clinical pipeline, including continued advancement of investigational CD47-blocker ...

Dosing has started in a clinical evaluating peluntamig, which targets DLL3 and CD47, combined with chemotherapy in patients with DLL3-expressing cancers.

Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable ...